58.3 percent of rh-irAEs were glucocorticoid refractory and 53.3 percent required second-line immunomodulatory therapy
TUESDAY, Sept. 22, 2026 (HealthDay News) — For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to permanent ICI discontinuation, according to a study published online Sept. 8 in ACR Open Rheumatology.
Didzis Gailis, M.D., from the Ludwig-Maximilians-Universität University Hospital in Munich, and colleagues describe clinical phenotypes, treatment, and outcomes of rh-irAEs in a multicenter, observational registry of adults receiving ICIs.
Sixty patients were included as of Jan. 1, 2026; the main malignancy was melanoma (40.0 percent). The researchers found that the leading phenotype was rheumatoid arthritis-like polyarthritis, followed by polymyalgia rheumatica-like and peripheral spondyloarthritis-like syndrome (41.7, 18.3, and 11.7 percent, respectively). Younger patients had axial spondyloarthritis-like syndrome. Ninety percent had moderate or severe rh-irAEs; 23.3 and 38.3 percent required hospitalization and permanently discontinued ICIs, respectively. Eighty-five percent used systemic glucocorticoids (GCs); 58.3 and 53.3 percent were GC-refractory and required second-line immunomodulatory therapy, respectively. Overall, 33.3 and 51.7 percent achieved complete remission and partial remission, respectively. Fifteen percent had oncological progression; 28.1 percent of patients required second-line therapy. The strongest predictor of second-line systemic therapy was male sex.
“Strikingly, 53.3 percent of patients required immunomodulatory therapy beyond GCs,” the authors write. “The therapeutic demand of rh-irAEs, particularly in a rheumatologists-referred setting, is greater than previously reported.”
Several authors disclosed ties to the biopharmaceutical and health care industries.
ESMO: Combination Treatment Improves Survival in Muscle-Invasive Bladder Cancer
Threshold Oral Food Challenge Can Delabel Infants With Peanut Allergy
Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in RA
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
CDC: 1 in 10 U.S. Adults Reported GLP-1 Medication Use July to August 2025
β3 Agonists Do Not Cut Dementia Risk Versus Anticholinergics in OAB
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy